MA56060A - Dosage de lymphocytes t ayant subi une expansion - Google Patents
Dosage de lymphocytes t ayant subi une expansionInfo
- Publication number
- MA56060A MA56060A MA056060A MA56060A MA56060A MA 56060 A MA56060 A MA 56060A MA 056060 A MA056060 A MA 056060A MA 56060 A MA56060 A MA 56060A MA 56060 A MA56060 A MA 56060A
- Authority
- MA
- Morocco
- Prior art keywords
- expanded
- lymphocyte assay
- lymphocyte
- assay
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 238000002794 lymphocyte assay Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4201—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962855718P | 2019-05-31 | 2019-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56060A true MA56060A (fr) | 2022-04-06 |
Family
ID=73552967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056060A MA56060A (fr) | 2019-05-31 | 2020-05-29 | Dosage de lymphocytes t ayant subi une expansion |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220236253A1 (fr) |
| EP (1) | EP3976057A4 (fr) |
| JP (1) | JP2022535006A (fr) |
| AU (1) | AU2020283030A1 (fr) |
| CA (1) | CA3142352A1 (fr) |
| MA (1) | MA56060A (fr) |
| WO (1) | WO2020243561A1 (fr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015249553B2 (en) | 2014-04-23 | 2021-03-04 | Modernatx, Inc. | Nucleic acid vaccines |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| MA42543A (fr) | 2015-07-30 | 2018-06-06 | Modernatx Inc | Arn épitope peptidiques concatémériques |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| MA47016A (fr) | 2015-10-22 | 2018-08-29 | Modernatx Inc | Vaccins contre les virus respiratoires |
| US11643441B1 (en) | 2015-10-22 | 2023-05-09 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (VZV) |
| WO2017070624A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins contre des maladies tropicales |
| EP3364981A4 (fr) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | Vaccin contre le cytomégalovirus humain |
| WO2017099823A1 (fr) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Compositions et procédés permettant d'administrer des agents thérapeutiques |
| US12128113B2 (en) | 2016-05-18 | 2024-10-29 | Modernatx, Inc. | Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome |
| JP6983455B2 (ja) | 2016-09-14 | 2021-12-17 | モデルナティーエックス, インコーポレイテッド | 高純度rna組成物及びその調製のための方法 |
| EP3528821A4 (fr) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | Vaccin contre le cytomégalovirus humain |
| WO2018089851A2 (fr) | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Vaccin antigrippal |
| MA50335A (fr) | 2016-12-08 | 2020-08-19 | Modernatx Inc | Vaccins à acide nucléique contre des virus respiratoires |
| WO2018111967A1 (fr) | 2016-12-13 | 2018-06-21 | Modernatx, Inc. | Purification par affinité d'arn |
| WO2018170245A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin à large spectre contre le virus de la grippe |
| US11464848B2 (en) | 2017-03-15 | 2022-10-11 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170270A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus varicelle-zona |
| WO2018170347A1 (fr) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Vaccins à base d'arn contre des maladies zoonotiques |
| MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
| WO2018232357A1 (fr) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Formulations d'arn |
| MA49914A (fr) | 2017-08-18 | 2021-04-21 | Modernatx Inc | Procédés analytiques par hplc |
| EP3668979A4 (fr) | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | Procédés pour analyse par clhp |
| JP7408098B2 (ja) | 2017-08-18 | 2024-01-05 | モデルナティエックス インコーポレイテッド | Rnaポリメラーゼバリアント |
| AU2018326799A1 (en) | 2017-08-31 | 2020-02-27 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| JP7526168B2 (ja) | 2018-09-19 | 2024-07-31 | モデルナティエックス インコーポレイテッド | Peg脂質及びそれらの使用 |
| MA53652A (fr) | 2018-09-19 | 2021-07-28 | Modernatx Inc | Lipides peg de haute pureté et leurs utilisations |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| WO2020172239A1 (fr) | 2019-02-20 | 2020-08-27 | Modernatx, Inc. | Variants d'arn polymérase pour le coiffage co-transcriptionnel |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| WO2020185811A1 (fr) | 2019-03-11 | 2020-09-17 | Modernatx, Inc. | Procédé de transcription in vitro à alimentation semi-discontinue |
| WO2020190750A1 (fr) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Vaccins à base d'arn contre le vih |
| CN115811986A (zh) | 2020-04-22 | 2023-03-17 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| WO2024002985A1 (fr) | 2022-06-26 | 2024-01-04 | BioNTech SE | Vaccin contre le coronavirus |
| EP4648793A1 (fr) | 2023-01-11 | 2025-11-19 | ModernaTX, Inc. | Vaccins anticancéreux personnalisés |
| WO2024231621A1 (fr) * | 2023-05-05 | 2024-11-14 | Centre National De La Recherche Scientifique | Acide nucleique synthetique et ses utilisations therapeutiques |
| WO2025083147A1 (fr) * | 2023-10-17 | 2025-04-24 | Transimmune Ag | Procédés d'analyse de réponses immunitaires et de profilage d'antigènes |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2697367B1 (fr) * | 2011-04-13 | 2018-12-19 | Immunicum AB | Procédé pour faire proliférer des cellules t spécifiques d'antigènes |
| US20180171294A1 (en) * | 2015-03-26 | 2018-06-21 | The Trustees Of The University Of Pennsylvania | In vitro artificial lymph node method for sensitization and expansion of t cells for therapy and epitope mapping |
| EP3494209A1 (fr) * | 2016-08-05 | 2019-06-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Génération ex vivo de cellules t régulatrices cd4+ foxp3+ restreintes au cmh ii et utilisations thérapeutiques de ces dernières |
| KR20240117650A (ko) * | 2017-02-01 | 2024-08-01 | 모더나티엑스, 인크. | Rna 암 백신 |
| WO2019196088A1 (fr) * | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Procédés d'obtention de récepteurs de lymphocytes t spécifiques d'une tumeur |
-
2020
- 2020-05-29 MA MA056060A patent/MA56060A/fr unknown
- 2020-05-29 US US17/615,202 patent/US20220236253A1/en active Pending
- 2020-05-29 WO PCT/US2020/035307 patent/WO2020243561A1/fr not_active Ceased
- 2020-05-29 AU AU2020283030A patent/AU2020283030A1/en not_active Abandoned
- 2020-05-29 JP JP2021571011A patent/JP2022535006A/ja active Pending
- 2020-05-29 EP EP20813362.9A patent/EP3976057A4/fr active Pending
- 2020-05-29 CA CA3142352A patent/CA3142352A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3976057A4 (fr) | 2023-08-30 |
| CA3142352A1 (fr) | 2020-12-03 |
| EP3976057A1 (fr) | 2022-04-06 |
| JP2022535006A (ja) | 2022-08-04 |
| US20220236253A1 (en) | 2022-07-28 |
| AU2020283030A1 (en) | 2021-12-23 |
| WO2020243561A1 (fr) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56060A (fr) | Dosage de lymphocytes t ayant subi une expansion | |
| EP3964303A4 (fr) | Système de tri | |
| EP3858852A4 (fr) | Récepteur de lymphocytes t reconnaissant un antigène ssx2 | |
| EP3857419A4 (fr) | Détection de logiciel rançonneur | |
| EP3897523A4 (fr) | Microcapsules préparées à partir de protéines | |
| HUE056564T2 (hu) | Rendszerek plazmagyûjtõ térfogatok optimalizálására | |
| MA47359A (fr) | Récepteurs de lymphocytes t à appariement amélioré | |
| MA44608A (fr) | Récepteurs des lymphocytes t | |
| EP3915339C0 (fr) | Système d'éclairage à gradation biologique | |
| EP3523162A4 (fr) | Ensemble rétroviseur ayant une détection d'occupant | |
| EP3491667A4 (fr) | Système de commutateur à semi-conducteur | |
| EP4352545A4 (fr) | Détection de proximité | |
| HUE065929T2 (hu) | Mozgó tárgyak válogatására szolgáló egység | |
| EP3291916A4 (fr) | Dosage immunologique à base de particules avec électrocinétique en courant alternatif | |
| IL277795A (en) | Spin-on metallization | |
| EP3953838A4 (fr) | Moteur de recherche intelligent | |
| EP3806192A4 (fr) | Séparateur multicouche | |
| EP3810563A4 (fr) | Dosages multiplex protéomiques améliorés | |
| DK3983129T3 (da) | Cyklonisk separator | |
| EP3950157A4 (fr) | Trieuse | |
| DK3883374T3 (da) | Cyklonseparationssystem | |
| PT3599479T (pt) | Deteção de projéteis | |
| EP3887658C0 (fr) | Système de post-traitement | |
| EP4202802A4 (fr) | Système de classification | |
| EP4081119C0 (fr) | Système d'élimination |